Organisation paid for research Program year 2025 Source: CMS Open Payments

Health Concepts

Neither a doctor nor a teaching hospital

Research payments

$424,291

95 payments

Through program year 2025, Health Concepts is reported as receiving $424,291 in research payments, across 95 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$16,471	1
2024	Research	$158,903	8
2023	Research	$40,401	14
2022	Research	$66,672	9
2021	Research	$41,273	5
2020	Research	$59,964	25
2019	Research	$40,605	33

Breakdown

Who paid Research payments · program years 2019–2025

E.R. Squibb & Sons, L.L.C. $155,152 5 payments
Amgen Inc. $94,102 7 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $71,005 10 payments
Dr.Reddy's Laboratories,Inc. $26,964 8 payments
Kowa Research Institute, Inc. $26,502 4 payments
Pfizer Inc. $22,412 12 payments
Boehringer Ingelheim International GmbH $9,687 8 payments
Teva Pharmaceuticals USA, Inc. $8,128 4 payments
AbbVie, Inc. $3,648 4 payments
Merck Sharp & Dohme Corporation $2,500 1 payment

Studies the money was for Research payments · program years 2019–2025

Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis $79,681 3 payments
Phase 2b POC PsO Study - A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986322 in Participants with Moderate-to-Severe Psoriasis $73,422 1 payment
BI 730357 PoCC and dose ranging in Psoriasis $40,035 5 payments
ASCEND P3 AD Extension $39,415 2 payments
BI 730357 Psoriasis Long Term Extension $30,971 5 payments
OUTPOST Clinical Home Use Study $29,731 2 payments
Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis $26,964 8 payments
K-877-Er-201 $20,386 3 payments
Access Barriers to Pfizer Clinical Trials in the United States $18,270 1 payment
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) $16,471 1 payment

What the money was spent on Research payments · program years 2019–2025

Other $1,500 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.